SINOPHARM TECH (08156) announced its interim results for the six months ended December 31, 2025. Revenue reached HK$26.769 million, representing a year-on-year increase of 41.65%. The loss attributable to the company's shareholders was HK$3.681 million, narrowing by 33.23% compared to the same period last year. The basic loss per share was HK$0.58 cent.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.